Omnicell (NASDAQ:OMCL) Stock Rating Upgraded by Zacks Research

Omnicell (NASDAQ:OMCL) was upgraded by research analysts at Zacks Research from a “hold” rating to a “strong-buy” rating in a report released on Wednesday, Zacks reports.

A number of other equities analysts also recently issued reports on the stock. Wells Fargo & Company lowered their price objective on shares of Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, July 31st. Weiss Ratings raised Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 18th. KeyCorp reissued an “overweight” rating on shares of Omnicell in a research report on Monday, August 24th. Finally, Piper Sandler restated an “overweight” rating and issued a $45.00 target price (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Omnicell presently has a consensus rating of “Buy” and a consensus target price of $57.86.

Omnicell Stock Down 3.5%

Shares of Omnicell stock opened at $38.03 on Wednesday. The company has a current ratio of 1.65, a quick ratio of 1.45 and a debt-to-equity ratio of 0.13. The company’s fifty day simple moving average is $34.85 and its two-hundred day simple moving average is $38.84. The company has a market cap of $1.73 billion, a P/E ratio of 39.61, a PEG ratio of 0.98 and a beta of 0.88. Omnicell has a 12-month low of $31.75 and a 12-month high of $55.00.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings data on Thursday, October 29th. The company reported $0.58 EPS for the quarter, topping the consensus estimate of $0.42 by $0.16. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The business had revenue of $307.85 million during the quarter, compared to analyst estimates of $304.44 million. During the same period in the prior year, the business earned $0.51 EPS. The company’s revenue for the quarter was down .9% on a year-over-year basis. Research analysts anticipate that Omnicell will post 1.64 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Nykredit A S purchased a new position in Omnicell during the 2nd quarter valued at about $26,000. Versant Capital Management Inc grew its holdings in Omnicell by 38.7% in the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after purchasing an additional 294 shares during the period. Fulcrum Asset Management LLP grew its holdings in Omnicell by 2,536.4% in the third quarter. Fulcrum Asset Management LLP now owns 1,160 shares of the company’s stock worth $40,000 after purchasing an additional 1,116 shares during the period. Northwestern Mutual Wealth Management Co. bought a new position in shares of Omnicell during the second quarter valued at approximately $105,000. Finally, Nisa Investment Advisors LLC increased its stake in shares of Omnicell by 21.9% during the third quarter. Nisa Investment Advisors LLC now owns 2,613 shares of the company’s stock valued at $89,000 after purchasing an additional 469 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Trending Headlines about Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Zacks said solid upward earnings-estimate revisions could support further near-term gains, and added OMCL to its Rank #1 (Strong Buy) lists for November 5, including its momentum and value selections. Why Omnicell Might be Well Poised for a Surge New Strong Buy Stocks
• Positive Sentiment: Analyst price targets imply substantial potential upside, with one report citing a consensus target of $57.86 and another estimating 40.8%. The article cautions that price targets alone have limited predictive value; estimate revisions may be a more meaningful near-term signal. Omnicell Consensus Target Price Omnicell Potential Rally
• Neutral Sentiment: Omnicell was included in a roundup of robotics stocks with long-term growth potential, but the article offered no new company-specific catalyst. Top Robotics Stocks
• Negative Sentiment: The recent earnings backdrop is mixed: Omnicell beat quarterly EPS and revenue estimates, but revenue was down 0.9% year over year. That modest decline may temper optimism around the positive estimate-revision signals.

Omnicell Company Profile

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.